TERN
Terns Pharmaceuticals, Inc.42.92
-1.09-2.48%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.67BP/E (TTM)
-Basic EPS (TTM)
-1.02Dividend Yield
0%Recent Filings
10-K
8-K
Merck to buy Terns at $53/share
Terns Pharmaceuticals signed a merger agreement with Merck on March 24, 2026, for Merck to acquire all shares at $53.00 each via tender offer, followed by merger. Merck targets TERN-701, Terns' Phase 1/2 CML candidate, to bolster its hematology pipeline. Deal hinges on HSR clearance; $235M termination fee if Terns pursues superior offer. Closing eyed for Q2 2026.
8-K
Terns grabs exclusive TERN-701 rights
Terns Pharmaceuticals amended its license agreement with Hansoh on January 16, 2026, securing an exclusive, worldwide (ex-Hansoh Territory) license to Hansoh's TERN-701 patents for $1.0 million upfront plus 0.75-1.25% tiered royalties on net sales. This upgrades Terns' prior non-exclusive access. Rights expand globally. Patents cover key oncology asset.
8-K
TERN-701 milestones, $1B cash
Terns Pharmaceuticals outlined 2026 priorities for TERN-701, its allosteric BCR-ABL inhibitor for CML, at the J.P. Morgan Healthcare Conference on January 12. CARDINAL Phase 1/2 enrollment accelerates, targeting pivotal dose selection and FDA interaction mid-2026, expanded data in 2H26, and 2L+ pivotal trial start late 2026. Cash hit ~$1.0B end-2025, funding into 2031. Strong runway fuels rapid pivot to launch.
8-K
Upsized $706M offering priced
Terns Pharmaceuticals priced an upsized public offering of 18,687,500 shares at $40.00 each on December 9, 2025, expecting $705.8 million in net proceeds after full exercise of the underwriters' option; closing set for December 11. Funds will support clinical trials and development of key candidates like TERN-701. Cash runway now extends into 2031. Closing hinges on customary conditions.
ALT
Altimmune, Inc.
5.03-0.25
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
KROS
Keros Therapeutics, Inc.
21.53+0.30
LTRN
Lantern Pharma Inc.
3.33-0.04
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MTSR
Metsera, Inc.
70.50-0.25
SEPN
Septerna, Inc.
26.23-0.95
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09
TCRX
TScan Therapeutics, Inc.
0.95-0.01